European Commission
Public Health
Accessibility tools
Service tools
Language selector
- Current languageen
Navigation path
- European Commission
- Public health
- Reference documents
- Register
- Orphan products
- HLA class I/II binding tumour associated peptides (ADF-APO-C
Community Register of medicinal products
Community register of orphan medicinal products | GRANTED |
Product information |
HLA class I/II binding tumour associated peptides (ADF-APO-CCN-GUC-K67-MET- MMP-MUC-RGS)
| EU orphan designation number: | EU/3/07/433
|
| Active ingredient: | HLA class I/II binding tumour associated peptides (ADF-APO-CCN-GUC-K67-MET- MMP-MUC-RGS) |
| Indication: | Treatment of renal cell carcinoma |
| Sponsor: | Immatics Biotechnologies GmbH
Paul-Ehrlich-Str. 15, D-72076 Tuebingen, Deutschland |
Public summary of scientific opinion
European Commission procedures
| Close date procedure | Procedure type | EMEA number | Decision | summary publ | decision docs | annex |
| 19/02/2007 | Centralised Orphan - Designation | EMEA/OD/059/06 | (2007)538 of 15/02/2007 |